Pulmonary adenosquamous carcinoma with mucoepidermoid carcinoma-like component with characteristic p63 staining pattern: either a novel subtype originating from bronchial epithelium or variant mucoepidermoid carcinoma.

Background: Our previous study found unique adenosquamous carcinomas (ADSQs) containing a mucoepidermoid carcinoma (MEC)-like component and a characteristic p63 staining pattern. This study focused on these unique ADSQs.

Methods: Thirty ADSQ cases were studied histologically and by immunohistochemistry for TTF-1 and p63.

Variation in (18)F-FDG PET findings in a patient with synchronous multiple thymoma.

We herein present a case of synchronous multiple thymoma that was suspected based on the findings of positron emission tomography with fluorine-18-labeled-fluorodeoxyglucose ((18)F-FDG PET). The patient was a 70-year-old male with two similarly sized and heterogeneously enhanced masses on the right side of the anterior mediastinum on chest computed tomography. (18)F-FDG PET revealed variation in FDG accumulation between the masses, in which the maximum standardized uptake value was 4.

A clinicopathological and immunohistological re-evaluation of adenosquamous carcinoma of the lung.

Since the World Health Organization histological criteria were published in 1999, several studies have focused on adenosquamous carcinoma of the lung. Therefore, we aimed to clinicopathologically re-evaluate this tumor using immunohistochemical methods. In our hospital, there have been 21 surgically resected adenosquamous carcinomas.

Expression of podoplanin in thymoma: its correlation with tumor invasion, nodal metastasis, and poor clinical outcome.

Recent studies have shown that podoplanin overexpression is associated with lymph node metastasis and poor clinical outcome in several malignant tumors. To investigate the role of podoplanin in thymoma, we examined 111 thymomas by immunohistochemistry using monoclonal antibody D2-40, which recognizes podoplanin. The tumors consisted of 8 type A, 40 type AB, 15 type B1, 23 type B2, 15 type B3, and 10 combined thymomas according to the World Health Organization histological classification system and of 41 stage I, 28 stage II, 16 stage III, 20 stage IVa, and 6 stage IVb thymomas according to the Masaoka staging system.